Clinical

The company did not recover from the 5 patient deaths associated with JCAR015 in 2016.

By the time the opioid epidemic was dominating headlines, it was already out of control. So how did the epidemic sneak up on the United States, and what is being done at the state and federal levels to combat the issue?

A vitamin D deficit may be linked with irritable bowel syndrome (IBS) in children. According to a new study published in PLOS ONE, more than 90% of pediatric patients with IBS were deficient in vitamin D.

Median overall survival was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial.

Expanding a health system pharmacy’s operations to include specialty drugs, namely oral oncology agents, improved patient care by reducing errors and saving costs.

The National Organization for Rare Disorders has announced a new, yearlong campaign to raise public awareness of rare diseases. “Do Your Share for Rare” shines a light on people living with a rare disease and provides an opportunity for them to share their story.

Precision medicine has demonstrated clinical utility and cost-effectiveness, which is why many believe this approach will be key to value-based cancer care in the future, said Jonathan Hirsch, founder and president of Syapse.

This week, the top managed care stories included Republicans releasing an outline for replacing the Affordable Care Act, pharmacy benefit managers and pharmaceutical companies pointing fingers over drug costs, and findings on engagement for patients with chronic conditions.

Using body composition metrics to guide the dose in patients receiving anthracyclines-taxane—based chemotherapy for breast cancer can reduce treatment-related toxicity.

Population-level judgements on the value of therapies to treat multiple sclerosis don’t adequately depict the differences between how providers and payers view value compared with patients and how patients view value different from one another.

Including anti-cholesterol agents during adjuvant endocrine treatment can prevent breast cancer recurrence in hormone receptor—positive early-stage breast cancer.

Pam Mangat, MS, associate director for the TAPUR study in the research and analysis division of the American Society of Clinical Oncology, offered an update on the study at the 5th annual Patient-Centered Oncology Care® meeting.

David L. Porter, MD, kicked off the 5th annual Patient-Centered Oncology Care® (PCOC®) meeting in Baltimore on November 17, 2016, with an update on chimeric antigen receptor T-cell therapy.

At the 5th annual Patient-Centered Oncology Care® meeting, hosted by The American Journal of Managed Care®, experts discussed the contradiction presented by immuno-oncology agents in the world of precision medicine.

The trial successfully improved progression-free survival and also tested a BRCA diagnostic test in patients with ovarian cancer.

Surrogate endpoints could eventually add to or replace clinical endpoints in determining a cancer treatment’s effectiveness, according to Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology. She also said that a deeper understanding of a patient’s genetic makeup and tumor biology in conjunction with new technologies will drive improvements in oncology care.

An oncologist provides insight on his experience with using CAR-T therapy in the clinic and his prediction for the future of this revolutionary treatment.

A new treatment option using stem cell transplants was shown to induce sustained remission of relapsing-remitting multiple sclerosis (MS). More than two-thirds of participants had no signs of progression of disability, relapse of MS symptoms, or new brain lesions after 5 years.

Observational findings from the Women’s Health Initiative study found that an intentional weight loss regimen by postmenopausal obese women can slash their risk of endometrial cancer by 29% to 56%.

A new study published in the Journal of the National Comprehensive Cancer Network dives deeper into understanding the major roadblocks to coverage of hereditary cancer panels.